Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906362930> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2906362930 endingPage "S54" @default.
- W2906362930 startingPage "S54" @default.
- W2906362930 abstract "Accelerated marketing authorization (AMA) aims to make medicines with a major public health impact available as quickly as possible. Although accelerated approval pathways in the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have reduced review time to approval, evidence of the use of AMA remains sparse. Study objectives: Estimate time to approval using accelerated pathways by the EMA and FDA since 2015 Estimate time to approval in AMA pathways for other developed countries: Health Canada, PMDA (Japan) and TGA (Australia) comparing with EMA and FDA Describe differences between agencies that may influence time to decision. We identified drugs approved by FDA and EMA since 2015 that used AMA. Findings were cross-checked with databases for Health Canada, PMDA and TGA. Information extracted included: drug name, indication, submission and approval dates. Average time to approval was compared across the five agencies. Of the 11 drugs granted accelerated approval by EMA and FDA, 10 were considered under AMA pathways in Japan, four in Canada and zero in Australia. Four-fifths of the indications were for oncology. The median (range) time to approval in days was: 158 (91, 298) for FDA, 238 (204, 264) for Health Canada, 253 (220, 313) for PMDA and 287 (217, 527) for EMA. The criteria to grant AMA varied across agencies. There were noticeable differences in the approach to AMA in the five agencies. The list of drugs with AMA in Japan reflected the inclusion in accelerated pathways in FDA and EMA. Coverage was lower in Canada and Australia. FDA AMA pathways offered the fastest access to market. AMA pathways can facilitate quicker patient access to breakthrough medicines, although there may be further delays for reimbursement. AMA pathways remain underused in Canada and Australia." @default.
- W2906362930 created "2019-01-01" @default.
- W2906362930 creator A5006578020 @default.
- W2906362930 creator A5037310759 @default.
- W2906362930 creator A5057603890 @default.
- W2906362930 creator A5077277501 @default.
- W2906362930 date "2018-10-01" @default.
- W2906362930 modified "2023-09-30" @default.
- W2906362930 title "PCN238 - TIME TO APPROVAL USING ACCELERATED MARKETING AUTHORIZATION PATHWAYS: A STUDY OF FIVE DEVELOPED COUNTRIES" @default.
- W2906362930 doi "https://doi.org/10.1016/j.jval.2018.09.320" @default.
- W2906362930 hasPublicationYear "2018" @default.
- W2906362930 type Work @default.
- W2906362930 sameAs 2906362930 @default.
- W2906362930 citedByCount "0" @default.
- W2906362930 crossrefType "journal-article" @default.
- W2906362930 hasAuthorship W2906362930A5006578020 @default.
- W2906362930 hasAuthorship W2906362930A5037310759 @default.
- W2906362930 hasAuthorship W2906362930A5057603890 @default.
- W2906362930 hasAuthorship W2906362930A5077277501 @default.
- W2906362930 hasBestOaLocation W29063629301 @default.
- W2906362930 hasConcept C108170787 @default.
- W2906362930 hasConcept C108759981 @default.
- W2906362930 hasConcept C111472728 @default.
- W2906362930 hasConcept C138885662 @default.
- W2906362930 hasConcept C2777589142 @default.
- W2906362930 hasConcept C2780035454 @default.
- W2906362930 hasConcept C2992293740 @default.
- W2906362930 hasConcept C3018890749 @default.
- W2906362930 hasConcept C38652104 @default.
- W2906362930 hasConcept C41008148 @default.
- W2906362930 hasConcept C512399662 @default.
- W2906362930 hasConcept C60644358 @default.
- W2906362930 hasConcept C71924100 @default.
- W2906362930 hasConcept C86803240 @default.
- W2906362930 hasConcept C98274493 @default.
- W2906362930 hasConcept C99454951 @default.
- W2906362930 hasConceptScore W2906362930C108170787 @default.
- W2906362930 hasConceptScore W2906362930C108759981 @default.
- W2906362930 hasConceptScore W2906362930C111472728 @default.
- W2906362930 hasConceptScore W2906362930C138885662 @default.
- W2906362930 hasConceptScore W2906362930C2777589142 @default.
- W2906362930 hasConceptScore W2906362930C2780035454 @default.
- W2906362930 hasConceptScore W2906362930C2992293740 @default.
- W2906362930 hasConceptScore W2906362930C3018890749 @default.
- W2906362930 hasConceptScore W2906362930C38652104 @default.
- W2906362930 hasConceptScore W2906362930C41008148 @default.
- W2906362930 hasConceptScore W2906362930C512399662 @default.
- W2906362930 hasConceptScore W2906362930C60644358 @default.
- W2906362930 hasConceptScore W2906362930C71924100 @default.
- W2906362930 hasConceptScore W2906362930C86803240 @default.
- W2906362930 hasConceptScore W2906362930C98274493 @default.
- W2906362930 hasConceptScore W2906362930C99454951 @default.
- W2906362930 hasLocation W29063629301 @default.
- W2906362930 hasOpenAccess W2906362930 @default.
- W2906362930 hasPrimaryLocation W29063629301 @default.
- W2906362930 hasRelatedWork W2050185736 @default.
- W2906362930 hasRelatedWork W2069316011 @default.
- W2906362930 hasRelatedWork W2474212275 @default.
- W2906362930 hasRelatedWork W2741557096 @default.
- W2906362930 hasRelatedWork W2898387476 @default.
- W2906362930 hasRelatedWork W2946910186 @default.
- W2906362930 hasRelatedWork W2999793242 @default.
- W2906362930 hasRelatedWork W3127951312 @default.
- W2906362930 hasRelatedWork W4280610033 @default.
- W2906362930 hasRelatedWork W630568403 @default.
- W2906362930 hasVolume "21" @default.
- W2906362930 isParatext "false" @default.
- W2906362930 isRetracted "false" @default.
- W2906362930 magId "2906362930" @default.
- W2906362930 workType "article" @default.